Testing the effectiveness of nanoparticle vaccines against lung infections in a murine lung infection model
Testing the effectiveness of nanoparticle vaccines against lung infections in a murine lung infection model
Parivash Ghaderinia1 Behdokht Jamali2 Marzieh Salehifard3 Azam Yaghoobi4 Farzaneh Hosseini5 Hooman Hanifehpour6
1) Department of Microbiology, Zanjan Branch, Islamic Azad University, Zanjan, Iran
2) Department of Microbiology and Genetics, Kherad Institute of Higher Education, Bushehr, Iran
3) Department of Microbiology, Faculty of Basic Sciences, Shahrekord Azad University, Shahrekord, Iran
4) Department of Microbiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5) Department of Microbiology, North Tehran Branch, Islamic Azad University, Tehran, Iran
6) Department of Microbiology, Institute of Avicenna Biomedical Sciences, Tehran, Iran
IOI Code
:
XKFK-AZKCDZ
Publication :
8th International Conference on Applied Researches in Science & Engineering (8carse.com)
Abstract :
Klebsiella pneumoniae can cause destructive changes to human lungs if aspirated. The present study aimed to evaluate the immunogenicity of the carriers of Poly lactic-co-glycolic acid (PLGA) and Methoxypoly(ethylene glycol) Poly(caprolactone) (MPEG-PCL) nanoparticles containing the capsular antigen of Klebsiella pneumoniae K2O1 in a model of pulmonary infection in mice as a vaccine candidate. Capsule antigen was extracted from K.pneumoniae K2O1 strain 1053 ATCC 10031 and transported with PLGA or MPEG-PCL nanoparticles as a vaccine in an animal model. The results of FT-IR and AFM confirmed the presence of antigen functional groups in the nanoparticle structure, and semi-spherical shape of the nanoparticles, respectively. The capsular polysaccharide was also used to evaluate the febrileness of the designed vaccine candidates based on the rabbits’ pattern, and mortality due to the vaccine candidates in the mice. No fever was observed, and no mortality was observed in the mice. According to the results, the vaccine candidates designed to control the cause of pulmonary infections were effective in the liver, spleen, and lungs of the animals with the ability to enter the first stage of the clinical trial phase.
Keywords : klebsiella pneumonia nanoparticle pulmonary infections vaccine